The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention
Status:
Recruiting
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
To compare the effect of different PrEP drugs (FTC-TDF and FTC-TAF), doses and timing of
doses on p24 antigen level in resected foreskin tissue following HIV exposure ex vivo
challenge.
Phase:
Phase 2
Details
Lead Sponsor:
Fatima Mayat Wits Health Consortium (Pty) Ltd
Collaborators:
Imperial College London Karolinska Institutet King's College London London School of Hygiene and Tropical Medicine MRC/UVRI Uganda Research Unit University of Cape Town University of Liverpool